Helmy KY, Patel SA, Nahas GR et al (2013) Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv 4(10):1307–1320

Article  CAS  PubMed  Google Scholar 

Gabora K, Piciu A, Bădulescu IC et al (2019) Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors. Drug Metab Rev 51(4):562–569

Article  CAS  PubMed  Google Scholar 

Bilen MA, Patel A, Hess KR et al (2016) Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol 78(1):167–171

Article  CAS  PubMed  Google Scholar 

Shu M, Zai X, Zhang B et al (2016) Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses. PLoS ONE 11(1):e147048

Article  Google Scholar 

Thomson RJ, Moshirfar M, Ronquillo Y (2023) Tyrosine Kinase Inhibitors. In StatPearls. StatPearls Publishing

Huang L, Jiang S, Shi Y (2020) Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). J Hematol Oncol 13:143

Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69:373–398

Article  CAS  PubMed  Google Scholar 

Trenker R, Jura N (2020) Receptor tyrosine kinase activation: from the ligand perspective. Curr Opin Cell Biol 63:174–185

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiménez G, Shvartsman SY, Paroush Z (2012) The Capicua repressor—a general sensor of RTK signaling in development and disease. J Cell Sci 125(Pt 6):1383–1391

Article  PubMed  PubMed Central  Google Scholar 

Hubbard SR, Miller WT (2007) Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 19(2):117–123

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen S, Liu H, Zhang Y (2020) Reported cardiovascular toxicity associated with paclitaxel antineoplastic drugs and literature analysis. Chin J New Drugs 29(20):2395–2400

Google Scholar 

Hochhaus A, Larson RA, Guilhot F et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917–927

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246

Article  CAS  PubMed  Google Scholar 

Lingyun C (2012) Clinical analysis of adverse reactions in the application of chemotherapeutic drugs for malignant tumors. China Practical Medicine 7(26):136–137

Google Scholar 

Wu J, Huang H (2020) Acquired hypothyroidism in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors 14:3977–3982

CAS  Google Scholar 

Pottier C, Fresnais M, Gilon M et al (2020) Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers 12(3):731

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhou Q, Wu Y (2019) Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives. Cancer Lett 459:240–247

Article  CAS  PubMed  Google Scholar 

Yan X, Wang H, Li P et al (2019) Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. Lung Cancer 128:6–12

Article  PubMed  Google Scholar 

Chen Y, Wei J, Cai J et al (2019) Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis. BMC Cancer 19:793 

Yin Y, Yuan X, Gao H et al (2020) Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. Int J Pharm 573:118785

Article  CAS  PubMed  Google Scholar 

Lechner MG, Vyas CM, Hamnvik OR et al (2018) Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers. Thyroid 28(4):445–453

Article  CAS  PubMed  Google Scholar 

De Leo S, Trevisan M, Moneta C et al (2023) Endocrine-related adverse conditions induced by tyrosine kinase inhibitors. Ann Endocrinol (Paris) 84(3):374–381

Article  PubMed  Google Scholar 

Basolo A, Matrone A, Elisei R et al (2022) Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. Semin Cancer Biol 79:197–202

Article  CAS  PubMed  Google Scholar 

Soni S, Rastogi A, Prasad KT et al (2021) Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort. Lung Cancer 151:16–19

Article  CAS  PubMed  Google Scholar 

Walko CM, Aubert RE, La-Beck NM et al (2017) Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib. Oncologist 22(2):208–212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kollmannsberger C (2016) Sunitinib side effects as surrogate biomarkers of efficacy. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 10(11–12Suppl7):S245–S247

Akaza H, Naito S, Ueno N et al (2015) Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients[J]. Jpn J Clin Oncol 45(6):576–583

Article  PubMed  PubMed Central  Google Scholar 

Bolzacchini E, Pinotti G, Bertu L et al (2020) On-target toxicities predictive of survival in metastatic renal cell carcinoma (mRCC) treated with sunitinib: a multicenter retrospective study. Clin Genitourin Cancer 18(2):e145–e156

Article  PubMed  Google Scholar 

Zygulska AL, Krzemieniecki K, Sowa-Staszczak A (2012) Hypothyroidism during treatment with tyrosine kinase inhibitors. Endokrynol Pol 63(4):302–306

CAS  PubMed  Google Scholar 

Shao Y, Cheng A, Hsu C (2021) An underdiagnosed hypothyroidism and its clinical significance in patients with advanced hepatocellular carcinoma. Oncologist 26(5):422–426

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roskoski RJ (2020) Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 152:104609

Article  CAS  PubMed  Google Scholar 

Shanafelt TD, Parikh SA, Noseworthy PA et al (2017) Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma 58(7):1630–1639

Article  CAS  PubMed  Google Scholar 

Fujino T, Suda K, Mitsudomi T (2020) Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opin Emerg Drugs 25(3):229–249

Article  CAS  PubMed  Google Scholar 

Salvatore D, Porcelli T, Ettleson MD et al (2022) The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol 10(5):366–372

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng X, Zhang H, Guan S et al (2023) Receptor modulators associated with the hypothalamus -pituitary-thyroid axis. Front Pharmacol 14:1291856

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luongo C, De Stefano MA, Ambrosio R et al (2023) Type 2 deiodinase Thr92Ala polymorphism and aging are associated with a decreased pituitary sensitivity to thyroid hormone. Thyroid 33(3):294–300

Article  CAS  PubMed  Google Scholar 

Biondi B, Cooper DS (2019) Thyroid hormone therapy for hypothyroidism. Endocrine 66(1):18–26

Article  CAS  PubMed  Google Scholar 

Shahid MA, Ashraf MA, Sharma S (2023) Physiology, Thyroid Hormone. In StatPearls

Mallya M, Ogilvy-Stuart AL (2018) Thyrotropic hormones. Best Pract Res Clin Endocrinol Metab 32(1):17–25

Article  CAS  PubMed  Google Scholar 

Braun D, Schweizer U (2018) Thyroid hormone transport and transporters. Vitam Horm 106:19–44

Article  CAS  PubMed  Google Scholar 

Singh S, Sandhu S (2023) Thyroid Disease and Pregnancy. In StatPearls

Sorisky A (2016) Subclinical hypothyroidism—what is responsible for its association with cardiovascular disease? Eur Endocrinol 12(2):96–98

PubMed  PubMed Central  Google Scholar 

Núñez A, Bedregal P, Becerra C et al (2017) Alteraciones del neurodesarrollo en pacientes con hipotiroidismo congénito: recomendaciones para el seguimiento [Neurodevelopmental assessment of patients with congenital hypothyroidism]. Rev Med Chil 145(12):1579–1587

Article  PubMed